Inzolfi (Fingolimod)

Fingolimod is phosphorylated inside the body and then binds to sphingosine‑1‑phosphate receptors on lymphocytes. This causes the receptors to be internalized, trapping lymphocytes in lymph nodes and preventing them from entering the central nervous system, thereby reducing autoimmune inflammation.

The prescribing physician determines the appropriate dose of Inzolfi based on clinical guidelines, patient weight, renal function, and other individual factors. Dosage decisions are made by the healthcare professional and should not be altered without medical advice.

Inzolfi is contraindicated during pregnancy because fingolimod can cause fetal harm. Women of childbearing potential must use effective contraception. The safety of fingolimod during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To request Inzolfi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative class for oral disease‑modifying therapy in multiple sclerosis includes dimethyl fumarate and other S1P modulators such as siponimod. Compared with dimethyl fumarate, fingolimod offers once‑daily dosing and a distinct mechanism of lymphocyte sequestration, but it may have a higher risk of cardiac and infection‑related adverse events.

Inzolfi should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appears discolored.

Inzolfi is taken orally as a tablet. The tablet should be swallowed whole with water, preferably at the same time each day, and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include cardiac events such as bradycardia or heart block, severe infections (including opportunistic infections), macular edema affecting vision, and significant liver enzyme elevations. Patients should report any new cardiac symptoms, visual changes, signs of infection, or jaundice promptly.

Inzolfi is contraindicated in pregnant women, individuals with recent myocardial infarction, unstable angina, stroke, or serious cardiac conduction disorders, and patients with severe liver impairment. It should also be avoided in those with known hypersensitivity to fingolimod or any of its excipients.